Food allergies are common and are associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy. In this trial, we assessed whether omalizumab, a ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Two weeks ago, the Food and Drug Administration approved Xolair ...

Please provide your email address to receive an email when new articles are posted on . Individuals received 8-week omalizumab followed by either 24-week dupilumab or placebo. The groups significantly ...

Please provide your email address to receive an email when new articles are posted on . Participants had allergies to up to three foods. Consumption included a median of 300 mg of their allergenic ...